Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ESMO 2014

Efficacy, tolerability and quality of life in metastatic renal cell carcinoma:...

Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France

Efficacy, tolerability and quality of life in metastatic renal cell carcinoma: Welcome and introduction ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )

mRCC: Are we doing all we can to manage adverse events?

Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France

mRCC: Are we doing all we can to manage adverse events? ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )

mRCC: Real-world experience: achieving efficacy beyond clinical trials

Dr Nizar Tannir - University of Texas M.D. Anderson Cancer Center, Houston, USA

mRCC: Real-world experience: achieving efficacy beyond clinical trials ( Dr Nizar Tannir - University of Texas M.D. Anderson Cancer Center, Houston, USA )

mRCC: Understanding the patient's perspective

Dr David Cella - Northwestern University, Chicago, USA

mRCC: Understanding the patient's perspective ( Dr David Cella - Northwestern University, Chicago, USA )

mRCC: Panel discussion

Prof Bernard Escudier, Dr Nizar Tannir, Dr David Cella

mRCC: Panel discussion ( Prof Bernard Escudier, Dr Nizar Tannir, Dr David Cella )

mRCC: Closing remarks

Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France

mRCC: Closing remarks ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )

Optimizing survival in advanced prostate cancer: Welcome and introduction

Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium

Optimizing survival in advanced prostate cancer: Welcome and introduction ( Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium )

Optimizing survival in advanced prostate cancer: Understanding PC heterogeneity...

Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium

Optimizing survival in advanced prostate cancer: Understanding PC heterogeneity to guide treatment choices ( Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium )

Optimizing survival in advanced prostate cancer: Tailoring mCRPC therapies to...

Prof Karim Fizazi - Institut Gustave Roussy, Paris, France

Optimizing survival in advanced prostate cancer: Tailoring mCRPC therapies to optimise survival ( Prof Karim Fizazi - Institut Gustave Roussy, Paris, France )

Optimizing survival in advanced prostate cancer: CHAARTED: What are the...

Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Optimizing survival in advanced prostate cancer: CHAARTED: What are the implications for the future? ( Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )

Optimizing survival in advanced prostate cancer: Learnings from real life...

Prof Bertrand Tombal - Saint-Luc Hospital, Brussels, Belgium

Optimizing survival in advanced prostate cancer: Learnings from real life practice ( Prof Bertrand Tombal - Saint-Luc Hospital, Brussels, Belgium )

Optimizing Survival in Advanced Prostate Cancer: Conclusion

Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium

Optimizing Survival in Advanced Prostate Cancer: Conclusion ( Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium )

Overall survival update from the BREAK-3 study

Prof Axel Hauschild - University Hospital Schleswig-Holstein, Kiel, Germany

Overall survival update from the BREAK-3 study ( Prof Axel Hauschild - University Hospital Schleswig-Holstein, Kiel, Germany )

Early events found to trigger lung cancer twenty years before diagnosis

Prof Charles Swanton - Cancer Research UK's London Research Institute, London...

Early events found to trigger lung cancer twenty years before diagnosis ( Prof Charles Swanton - Cancer Research UK's London Research Institute, London, UK )

Cancer Core Europe: Introduction

Prof Alexander Eggermont, Prof Carlos Caldas, Prof Ulrik Ringborg, Prof Jan...

Cancer Core Europe: Introduction ( Prof Alexander Eggermont, Prof Carlos Caldas, Prof Ulrik Ringborg, Prof Jan Schellens, Prof Alejandro Piris, Prof Thorston Zenz )

Cancer Core Europe: National Center for Tumor Diseases

Prof Thorston Zenz - National Center for Tumor Diseases, Heidelberg, Germany

Cancer Core Europe: National Center for Tumor Diseases ( Prof Thorston Zenz - National Center for Tumor Diseases, Heidelberg, Germany )

Cancer Core Europe: Vall d'Hebron Institute of Oncology

Prof Alejandro Piris - Vall d'Hebron Institute of Oncology, Barcelona, Spain

Cancer Core Europe: Vall d'Hebron Institute of Oncology ( Prof Alejandro Piris - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

Cancer Core Europe: Cancer Research UK Cambridge Institute

Prof Carlos Caldas - Cancer Research UK Cambridge Institute, Cambridge, UK

Cancer Core Europe: Cancer Research UK Cambridge Institute ( Prof Carlos Caldas - Cancer Research UK Cambridge Institute, Cambridge, UK )

Cancer Core Europe: Karolinska Institute

Prof Ulrik Ringborg - Karolinska Institute, Stockholm, Sweden

Cancer Core Europe: Karolinska Institute ( Prof Ulrik Ringborg - Karolinska Institute, Stockholm, Sweden )

Cancer Core Europe: Institut Gustave Roussy

Prof Lex Eggermont – Institut Gustave Roussy, Villejuif, France

Cancer Core Europe: Institut Gustave Roussy ( Prof Lex Eggermont – Institut Gustave Roussy, Villejuif, France )

Cancer Core Europe: Netherlands Cancer Institute

Prof Jan Schellens - Netherlands Cancer Institute, Amsterdam, Netherlands

Cancer Core Europe: Netherlands Cancer Institute ( Prof Jan Schellens - Netherlands Cancer Institute, Amsterdam, Netherlands )

Cancer Core Europe: Questions and answers

Prof Lex Eggermont, Prof Carlos Caldas, Prof Ulrik Ringborg, Prof Jan Schellens...

Cancer Core Europe: Questions and answers ( Prof Lex Eggermont, Prof Carlos Caldas, Prof Ulrik Ringborg, Prof Jan Schellens, Prof Piris, Prof Lenz )

Cancer Core Europe: Consortium to address the care-research continuum challenge

Prof Lex Eggermont, Prof Carlos Caldas, Prof Ulrik Ringborg

Cancer Core Europe: Consortium to address the care-research continuum challenge ( Prof Lex Eggermont, Prof Carlos Caldas, Prof Ulrik Ringborg )

ESMO 2014: News Roundup

ecancer News Team

ESMO 2014: News Roundup ( ecancer News Team )

ESMO 2014 Editor's roundup

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ESMO 2014 Editor's roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Ipilimumab extends relapse-free survival in resectable melanoma

Prof Alexander Eggermont - Gustave Roussy, Villejuif, France

Ipilimumab extends relapse-free survival in resectable melanoma ( Prof Alexander Eggermont - Gustave Roussy, Villejuif, France )

Prognostic biomarkers will detect lung cancer at earlier stages

Prof Giulia Veronesi - European Institute of Oncology, Milan, Italy

Prognostic biomarkers will detect lung cancer at earlier stages ( Prof Giulia Veronesi - European Institute of Oncology, Milan, Italy )

vandetanib improves PFS in thyroid cancer

Dr Enrique Grande - Hospital Universitario Ramón y Cajal, Madrid, Spain

vandetanib improves PFS in thyroid cancer ( Dr Enrique Grande - Hospital Universitario Ramón y Cajal, Madrid, Spain )

E-hospital: Fully coordinated cancer care and research in Europe

Prof Alexander Eggermont - Gustave Roussy, Villejuif, France

E-hospital: Fully coordinated cancer care and research in Europe ( Prof Alexander Eggermont - Gustave Roussy, Villejuif, France )

ESMO Highlights: Breast cancer

Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

ESMO Highlights: Breast cancer ( Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )

Combination of capecitabine and bevacizumab improves progression-free survival...

Dr Joseph Gligorov - Assistance Publique Hôpitaux de Paris, Paris, France

Combination of capecitabine and bevacizumab improves progression-free survival in metastatic breast cancer ( Dr Joseph Gligorov - Assistance Publique Hôpitaux de Paris, Paris, France )

Research shows chemotherapy has no negative effects on babies in utero

Prof Frederic Amant - University Hospital Leuven, Leuven, Belgium

Research shows chemotherapy has no negative effects on babies in utero ( Prof Frederic Amant - University Hospital Leuven, Leuven, Belgium )

Importance of gynaecological surgeons and multidisciplinary strategies in...

Dr Lucas Minig - Valencia Institute of Oncology, Valencia, Spain

Importance of gynaecological surgeons and multidisciplinary strategies in advanced ovarian cancer ( Dr Lucas Minig - Valencia Institute of Oncology, Valencia, Spain )

Raising awareness about head and neck cancer through the Make Sense campaign

Prof Jean-Louis Lefebvre, Northern France Comprehensive Cancer Centre, Lille...

Raising awareness about head and neck cancer through the Make Sense campaign ( Prof Jean-Louis Lefebvre, Northern France Comprehensive Cancer Centre, Lille, France )

Cancer care in developing countries

Prof Ian Magrath - International Network for Cancer Treatment and Research...

Cancer care in developing countries ( Prof Ian Magrath - International Network for Cancer Treatment and Research, Brussels, Belgium )

Treatment options in castration-resistant prostate cancer: Expert discussion

Prof Karim Fizazi, Prof Eleni Efstathiou, Dr Bertrand Tombal and Prof Stephane...

Treatment options in castration-resistant prostate cancer: Expert discussion ( Prof Karim Fizazi, Prof Eleni Efstathiou, Dr Bertrand Tombal and Prof Stephane Oudard )

Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma

Dr Caroline Robert - Gustave Roussy, Villejuif, France

Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma ( Dr Caroline Robert - Gustave Roussy, Villejuif, France )

Nivolumab potentially superior to standard chemo in advanced melanoma

Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA

Nivolumab potentially superior to standard chemo in advanced melanoma ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )

Targeted therapy for iodine-refractory thyroid cancer

Dr Makoto Tahara - National Cancer Center Hospital East, Kashiwa, Japan

$Targeted therapy for iodine-refractory thyroid cancer ( Dr Makoto Tahara - National Cancer Center Hospital East, Kashiwa, Japan )$

Young oncologists bridging the gap between translational and clinical cancer...

Prof Joan Seoane - Vall d’Hebron Institute of Oncology, Barcelona, Spain

Young oncologists bridging the gap between translational and clinical cancer research ( Prof Joan Seoane - Vall d’Hebron Institute of Oncology, Barcelona, Spain )

Questions raised about the future of lung cancer vaccination?

Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium

Questions raised about the future of lung cancer vaccination? ( Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium )

Cancer care as a human right in low-income countries

Prof Eduardo Cazap - SLACOM, Buenos Aires, Argentina

Cancer care as a human right in low-income countries ( Prof Eduardo Cazap - SLACOM, Buenos Aires, Argentina )

PD-L1 protein a possible immunotherapy target in mesothelioma

Prof Rolf Stahel - University Hospital of Zurich, Zurich, Switzerland

PD-L1 protein a possible immunotherapy target in mesothelioma ( Prof Rolf Stahel - University Hospital of Zurich, Zurich, Switzerland )

Improved response rate and survival with dabrafenib plus trametinib versus...

Dr Caroline Robert - Gustave Roussy, Villejuif, France

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma ( Dr Caroline Robert - Gustave Roussy, Villejuif, France )

Vemurafenib plus cobimetinib achieves significant progression-free survival in...

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )

Nivolumab shows signs of superior response rate compared to standard chemo in...

Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )

EORTC and the management of clinical trial data

Anastassia Negrouk - European Organisation for Research and Treatment of Cancer...

EORTC and the management of clinical trial data ( Anastassia Negrouk - European Organisation for Research and Treatment of Cancer, Brussels, Belgium and Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Improvements in progression free survival for patients with metastatic head and...

Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium

Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib ( Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium )

Financial impact of a cancer diagnosis

Prof Françoise Meunier - Director General of EORTC, Brussels, Belgium

Financial impact of a cancer diagnosis ( Prof Françoise Meunier - Director General of EORTC, Brussels, Belgium )

Combining cobimetinib and vemurafenib improves progression-free survival in...

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

Combining cobimetinib and vemurafenib improves progression-free survival in advanced melanoma ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )

Molecular targeting in cancer and the impact on personalised medicine

Prof Christian Dittrich - Ludwig Boltzmann Institute for Applied Cancer...

Molecular targeting in cancer and the impact on personalised medicine ( Prof Christian Dittrich - Ludwig Boltzmann Institute for Applied Cancer Research, Vienna, Austria )

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for...

Dr Sandra Swain - Washington Cancer Institute, Washington, USA

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )

Cediranib and chemo combo improves PFS for metastatic cervical cancer

Dr Raymond 'Paul' Symonds - University Hospital of Leicester, Leicester, UK

Cediranib and chemo combo improves PFS for metastatic cervical cancer ( Dr Raymond 'Paul' Symonds - University Hospital of Leicester, Leicester, UK )

Phase III trial results raise questions about the future of lung cancer...

Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium

Phase III trial results raise questions about the future of lung cancer vaccination ( Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium )

Little benefit for gefitinib-resistant lung cancer when continuing the drug...

Dr Tony Mok - The Chinese University of Hong Kong, Shatin, China

Little benefit for gefitinib-resistant lung cancer when continuing the drug with chemotherapy ( Dr Tony Mok - The Chinese University of Hong Kong, Shatin, China )

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for...

Dr Sandra Swain - Washington Cancer Institute, Washington, USA

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )

Adding cediranib to chemo improves PFS for metastatic cervical cancer

Dr Paul Symonds - University Hospital of Leicester, Leicester, UK

Adding cediranib to chemo improves PFS for metastatic cervical cancer ( Dr Paul Symonds - University Hospital of Leicester, Leicester, UK )

Helping cancer patients make sense of risk

Prof Rocio Garcia-Retamero - University of Granada, Granada, Spain

Helping cancer patients make sense of risk ( Prof Rocio Garcia-Retamero - University of Granada, Granada, Spain )

New horizons in prostate cancer: The final results of the COU-302 abiraterone...

Prof Charles Ryan and Prof Gordon McVie

New horizons in prostate cancer: The final results of the COU-302 abiraterone study ( Prof Charles Ryan and Prof Gordon McVie )

Reducing nausea and vomiting associated with cisplatin-based chemotherapy with...

Dr Bernardo Leon Rapoport - The Medical Oncology Centre, Johannesburg, South...

Reducing nausea and vomiting associated with cisplatin-based chemotherapy with rolapitant ( Dr Bernardo Leon Rapoport - The Medical Oncology Centre, Johannesburg, South Africa )

Rare cancers and the difficulties in making clinical decisions

Dr Paolo Casali - National Tumour Institute, Milan, Italy

Rare cancers and the difficulties in making clinical decisions ( Dr Paolo Casali - National Tumour Institute, Milan, Italy )

Anamorelin improves appetite and body mass in non-small cell lung cancer with...

Dr David Currow - Flinders University, Adelaide, Australia

Anamorelin improves appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia ( Dr David Currow - Flinders University, Adelaide, Australia )

Study shows chemotherapy and radiotherapy are safe for babies in utero

Prof Frederic Amant - University Hospital Leuven

Study shows chemotherapy and radiotherapy are safe for babies in utero ( Prof Frederic Amant - University Hospital Leuven )

Rolapitant reduces nausea and vomiting associated with cisplatin-based...

Dr Bernardo Leon Rapoport - The Medical Oncology Centre, Johannesburg, South...

Rolapitant reduces nausea and vomiting associated with cisplatin-based chemotherapy ( Dr Bernardo Leon Rapoport - The Medical Oncology Centre, Johannesburg, South Africa )

New drug anamorelin shows improvement in appetite and body mass in non-small...

Prof David Currow - Flinders University, Adelaide, Australia

New drug anamorelin shows improvement in appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia ( Prof David Currow - Flinders University, Adelaide, Australia )

Second-line afatinib significantly improves PFS in metastatic head and neck...

Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium

Second-line afatinib significantly improves PFS in metastatic head and neck cancer ( Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium )

More from ecancer